Hormone-Dependent Tumours of the Kidney

Bloom, H. J. G.; Baker, W H; Dukes, C. E.; Mitchley, B. C. V.

doi:10.1038/bjc.1963.82

Cited by 31 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous publications we have drawn attention to clinical, pathological and experimental evidence in support of the concept of a hormonal background to carcinoma of the kidney, and to the possibility of achieving worthwhile palliation in a small proportion of very advanced cases by the administration of gonadal hormones, chiefly progestins (Bloom et al, 1963a(Bloom et al, 1963bBloom and Wallace, 1964;Bloom, 1964Bloom, , 1967. Such agents appear to be not only more successful in controlling the disease than cytotoxic drugs, but are also remarkably free from serious side-effects following prolonged administration in large doses.…”

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

“…Provera combined with cortisone, but not alone, markedly reduced the growth rate of " independent " tumour transplants (Bloom et al, 1963a). Actual tumour regression was achieved by orchiectomy and this action was nullified by the administration of oestradiol (Bloom et al, 1963b). For this reason the effect of anti-oestrogens.was investigated and the first of these studied, U-llOOA (Upjohn Ltd.), a diphenyldihydronaphthaline derivative, had a marked inhibitory effect on the transplantable tumour .…”

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Bloom¹

1971

Br J Cancer

Self Cite

100

View full text Add to dashboard Cite

SUMMARY.-Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of cases had multiple metastases: in 76% more than one organ was involved and nearly 50% were seriously ill or " terminal ".Subjective improvement occurred in at least 55%. BETWEEN 75% and 80% of patients treated for renal cell carcinoma will die within 10 years of their primary treatment, the majority with distant metastases. In a few of these cases the natural history of the disease will be unusual. For example, growth of metastases may be exceptionally slow or, following removal of a solitary lesion, the patient may live for a number of years without further recurrence. Very rarely spontaneous regression of pulmonary deposits may occur. For the vast majority of cases, however, the onset of clinical metastases heralds death within a year or two. The treatment of advanced renal cancer with cytotoxic drugs has been disappointing. Woodruff et al. (1967) reviewed the literature on this subject, and of 243 collected cases treated with 33 different non-hormonal agents only 10% showed signs of objective improvement: in most instances this was slight or of brief duration. Talley et al. (1969) have published their personal experience with various cytotoxic drugs against metastatic hypernephroma. Of 57 patients treated with 15 different non-hormonal compounds, chiefly alkylating agents, antimetabolites and vinblastine, objective improvement was seen in only two cases (3.50 %). Apart from these poor results, the agents employed are highly toxic and have a relatively small margin of safety.

show abstract

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Bloom¹

1971

Br J Cancer

Self Cite

100

View full text Add to dashboard Cite

show abstract

“…Andererseits berichten einige Autoren [16,17] von generell günstigeren klinischen Verläufen, wenn eine Tumorerkrankung während der Schwangerschaft diagnostiziert wird. Erhöhte Östrogenspiegel begünstigen zwar das Wachstum einer renalen Neoplasie, dem gleichzeitig in der Schwangerschaft erhöhten Progesteron werden jedoch eher protektive Eigenschaften zugeschrieben [18]. Bis zum heutigen Zeitpunkt ist eine graviditätsinduzierte Tumordisposition oder Auswirkung auf den natürlichen Verlauf einer Tumorerkrankung nicht bewiesen.…”

unclassified

Das Nierenzellkarzinom in der Schwangerschaft

Poppel¹,

Altwein²

2001

Aktuel Urol

View full text Add to dashboard Cite

Einleitung Die maligne Tumorerkrankung zählt mit einer Inzidenz von ca. 1/1000 Schwangerschaften zu den seltenen, wenngleich außer-ordentlich schwerwiegenden Komplikationen einer Schwangerschaft [1]. Das Nierenzellkarzinom tritt bevorzugt ab der fünften Lebensdekade und somit im Vergleich zum Mamma-oder Zervixkarzinom seltener während einer Schwangerschaft auf [2, 3]. Der Trend zur Reproduktion in späteren Lebensjahren dürfte jedoch mit einer zunehmenden Inzidenz für renale Neoplasien während der Schwangerschaft einhergehen. Anhand von zwei Kasuistiken wird die Problematik des Nierenzellkarzinoms in der Gravidität diskutiert. KasuistikBei einer 22-jährigen Zweitgravida (2. Para) wurde in der 26. Schwangerschaftswoche im Rahmen der sonographischen Abklärung einer Harnwegsinfektion ein 7 × 12,5 cm großer Unterpoltumor der rechten Niere festgestellt. Die solide Raumforderung mit zystischen, randständig verkalkten Arealen war verdächtig für ein Nierenzellkarzinom. Sonographisch waren keine

show abstract

“…Bilateral orchiectomy prevents the grafted renal tumor from growing and inhibits further increase in size in well-established transplants. The effects of orchiectomy were completely nullified by simultaneous administration of estrogens (Bloom et al, 1963b). It appears that the transplanted tumor, although independent of administered stilbestrol, is still dependent upon endogenous estrogen derived from the adrenals and testes.…”

mentioning

confidence: 99%

“…It appears that the transplanted tumor, although independent of administered stilbestrol, is still dependent upon endogenous estrogen derived from the adrenals and testes. West feels that perhaps, in these circumstances, the action of testosterone may be explained on the basis of its conversion in the body to estrogens (Bloom et al, 1963b).…”

mentioning

confidence: 99%

Experimental aspects of renal tumors

Grabstald

1973

Journal of Surgical Oncology

View full text Add to dashboard Cite

Spontaneously observed and exogenously induced renal tumors in mice and rats have been described. Occasionally occurring tumors in other species have been reviewed. The relationships between the spontaneously observed and induced tumors and endocrine factors are reviewed. Practical applications for the use of induced tumors as screening techniques for chemotherapy of advanced renal cancer in man are discussed. Limitations in the present models are apparent. Both hormonal and nonhormonal environments can effect relative growth rates in several species of the induced tumors. Common metabolic pathways in several of the alkylating agents for the inductions of renal tumors are described. The virus relationships to frog tumors have been appreciated for some time and have becn further studied. Present clinical problems and controversies, however, remain. Important areas for further study of these models can provide helpful clinical information and have becn discussed.

show abstract

Hormone-Dependent Tumours of the Kidney

Cited by 31 publications

References 6 publications

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Das Nierenzellkarzinom in der Schwangerschaft

Experimental aspects of renal tumors

Contact Info

Product

Resources

About